SIETES :: 93212 citas

Resultados de la búsqueda por INTENCIÓN DE TRATAR REFINAR BÚSQUEDA

1.

Abraha I, Cherubini A, Cozzolino F, De Florio R, Luchetta ML, Rimland JM, Folletti I, Marchesi M, Germani A, Orso M, Eusebi P, Montedori A. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study. BMJ 2015;350:h2445. [Ref.ID 99147]

2.

Detry MA, Lewis RJ. The intention-to-treat principle: how to assess the true effect of choosing a medical treatment. JAMA 2014;312:85-6. [Ref.ID 97797]

3.

Hernán MA, Hernández-Díaz S, Robins JM. Randomized trials analyzed as observational studies. Ann Intern Med 2013;159:560-2. [Ref.ID 96385]

4.

Anónimo. Making sense of equivalence and non-inferiority trials. Australian Prescriber 2013;36:170-3. [Ref.ID 96321]

5.

6.

Patel MR, Fox KAA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Author/editor response. N Engl J Med 2011;365:2335. [Ref.ID 91975]

7.

Rosenstein R, Parra D. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:2334. [Ref.ID 91973]

8.

Rose A. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:2333-4. [Ref.ID 91972]

9.

Nessner A. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:2333. [Ref.ID 91971]

10.

White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011;342:910-2. [Ref.ID 90484]

11.

Sussman JB, Hayward RA. Using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ 2010;340:1181-4. [Ref.ID 88632]

12.

Schulz KF, Altman DG, Moher D, Fergusson D. CONSORT 2010 changes and testing blindness in RCTs. Lancet 2010;375:1144-6. [Ref.ID 88230]

13.

Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:698-702. [Ref.ID 88189]

14.

Antes G. The new CONSORT statement. BMJ 2010;340:666-7. [Ref.ID 88182]

15.

Giraudeau B, Ravaud P. Preventing bias in cluster randomised trials. PLOS Medicine 2009;6:1-6. [Ref.ID 85903]

16.

Anónimo. Understanding statistical terms: 3. Drug Ther Bull 2009;47:59-60. [Ref.ID 85827]

17.

Gotzsche P. Are new drugs for schizophrenia better than old ones?. Lancet 2009;373:1248. [Ref.ID 85614]

18.

Anónimo. Tests for equivalence or non-inferiority - why?. Drug Ther Bull 2008;46:55-6. [Ref.ID 83454]

19.

Karam R, Al-Khalidi H, Steinbuch M. Zoledronate, fractures, and mortality after hip fracture. N Engl J Med 2008;358:968. [Ref.ID 82300]

20.

Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, for the Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. A randomized trial. Ann Intern Med 2007;146:326-39. [Ref.ID 79534]